Skip to main content

Inmune Bio, Inc.

INMB
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001711754

No open-market purchases or sales by Inmune Bio, Inc. insiders were filed in the last 90 days; 82 institutions reported holding it in 13F filings for Q2 2026, worth $7.08M in total; no superinvestor holds it.

Q3 2025 vs. Q2 2025

How the institutions holding Inmune Bio, Inc. changed between Q2 2025 and Q3 2025.

All holders in Q3 2025All holders in Q2 2025

13F holders of INMB: Q2 2025 compared with Q3 2025
MeasureQ2 2025Q3 2025Change
Holders7973−6
Shares5.63M4.66M−970.1K (−17.2%)
Value$12.7M$9.64M−$3.09M (−24.3%)

New holders (16)

Institutions that held Inmune Bio, Inc. at the end of Q3 2025 but not at the end of Q2 2025.

Institutions new to INMB in Q3 2025
InstitutionSharesValue% of portfolio
Jane Street Group, LLC49,574$102.6K0.00%
Group One Trading, L.P.38,584$79.9K0.00%
Wolverine Trading, LLC29,193$61.6K0.00%
AQR Capital Management LLC20,306$42.0K0.00%
LMR Partners LLP16,600$34.4K0.00%
Squarepoint Ops LLC14,562$30.1K0.00%
Independent Advisor Alliance14,500$30.0K0.00%
Cary Street Partners Financial LLC13,917$28.8K0.00%
Russell Investments Group, Ltd.11,730$24.3K0.00%
SG Americas Securities, LLC10,784$22.0K0.00%
Rockefeller Capital Management L.P.2,500$5.17K0.00%
Close Asset Management Ltd2,000$4.00K0.00%
Principal Securities, Inc.619$1.28K0.00%
SRS Capital Advisors, Inc.490$1.01K0.00%
Optiver Holding B.V.158$3270.00%
Steward Partners Investment Advisory, LLC5$100.00%

Sold out (22)

Institutions that held Inmune Bio, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.